AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03760809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1μg／kg
Description: Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
Study NCT04518540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipoic acid group
Description: The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day.
Study NCT04518540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control group
Description: The patients will take domestic riluzole tablets 50mg orally, twice a day.
Study NCT01317901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-016
Description: 100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
Study NCT01317901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
Study NCT01317901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
Study NCT02198040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational group
Description: * Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique.
Study NCT03220880 — intervention group
Intervention type: DRUG
Intervention: Intranasal dexmedetomidine
Description: Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
Study NCT03083795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social relationships intervention
Description: Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
Study NCT04742868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT
Description: Quadriceps tendon with pattlar bone will used for grating
Study NCT01660893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Description: 3 unilateral intranasal sprays per dose
Study NCT01660893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3%
Description: 3 unilateral intranasal sprays per dose
Study NCT04742868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT
Description: Hamstring tendon with will used for grating
Study NCT04742868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT
Description: Quadriceps tendon without pattlar bone will used for grating
Study NCT04742868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: All patients will receive six months rehabilitation program which aim to recover the strength and function
Study NCT01074320 — intervention group
Intervention type: OTHER
Intervention: Other
Description: Observational study
Study NCT00545974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: memantine 10mg BID
Study NCT00545974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill BID
Study NCT03183661 — intervention group
Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-CD
Description: ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
Study NCT04460495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling Magnetic Resonance Imaging
Description: Undergo ASL scan
Study NCT04460495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pH-Weighted amine CEST
Description: Undergo pH Weighted amine CEST
Study NCT04460495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen-weighted SAGE-EPI
Description: Undergo Oxygen-weighted SAGE-EPI
Study NCT02398292 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: M3 Program
Description: Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
Study NCT02398292 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
Study NCT02442284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study NCT02442284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT02528149 — intervention group
Intervention type: PROCEDURE
Intervention: tissue of adjacent part and aneurysm of renal aneurysm
Description: the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
Study NCT02528149 — intervention group
Intervention type: OTHER
Intervention: blood sample
Study NCT02463500 — intervention group
Intervention type: OTHER
Intervention: DFU
Description: Standard care.
Study NCT01823575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone-covered metallic stent
Description: deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
Study NCT01823575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double-J stent
Description: Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
Study NCT04344431 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)
Description: One session per day of HBOT in addition to the standard treatment with normobaric oxygen
Study NCT01660893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 unilateral intranasal sprays per dose
Study NCT02242838 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT03672565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase One: Standardized Brief Intensive ERP
Description: Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
Study NCT03672565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phase Two: Flexible Patient Driven Intensive ERP
Description: Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~* They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~* They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~* They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially).
Study NCT03672565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Phase: Booster Calls
Description: Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
Study NCT02130596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavioral Intervention
Study NCT02130596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counselling
Study NCT02632188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative routine treatment
Description: Postoperative routine treatment according to the hospitals local routines
Study NCT02632188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative routine treatment
Description: Postoperative routine treatment according to the hospitals local routines
Study NCT03359252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-stent assisted coiling
Description: non-stent assisted coiling of unruptured intracranial aneurysm
Study NCT00666640 — intervention group
Intervention type: DEVICE
Intervention: DXA scan of hip
Description: Dual-energy X-ray Absorptiometry scan
Study NCT03359252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent assisted coiling
Description: stent assisted coiling of unruptured intracranial aneurysm
Study NCT00666640 — intervention group
Intervention type: DEVICE
Intervention: CT scan of hip
Description: Computed Tomography scan
Study NCT01579682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Therapy (FBT)
Description: 12 sessions of FBT over the course of 6 months.
Study NCT01579682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Therapy with Intensive Family-Focused treatment
Description: FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
Study NCT03798652 — intervention group
Intervention type: DEVICE
Intervention: Research CMR scan
Description: CMR scanning at a 3Tesla scanner at King's College London
Study NCT03798652 — intervention group
Intervention type: DEVICE
Intervention: Research 3D transthoracic echocardiogram
Description: The scan is required to assess left ventricular systolic function
Study NCT03798652 — intervention group
Intervention type: OTHER
Intervention: 6-minute walk test
Description: Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
Study NCT03601611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (RoACTEMRA®)
Description: Prednisolon will be given in case of worsening of symptoms
Study NCT04098003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: rosuvastatin 20 mg daily or placebo for eight weeks
Study NCT04098003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo control
Study NCT03564860 — intervention group
Intervention type: PROCEDURE
Intervention: Device data collection
Description: Collection of device electrograms and 12-lead ECG during a device follow-up visit
Study NCT00707551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Tablet, administered as repeated doses.
Study NCT00707551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Extended Release tablet, administered as repeated doses.
Study NCT00707551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended Release tablet, administered as a single dose.
Study NCT02632188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-PMAT treatment
Description: Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT02828852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed.
Study NCT00919620 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stage-specific case-management
Description: Stage-specific case-management for psychosis by designated key-workers according to specified protocol
Study NCT00919620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stage-specific case-management
Description: Stage-specific case-management for psychosis by designated key-workers according to specified protocol
Study NCT06342440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DENEB
Description: A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples.
Study NCT00409565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: * Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~* Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
Study NCT00409565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
Study NCT03373422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1128688
Description: Various dosing OD (once daily) and BID (twice daily)
Study NCT03373422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets
Study NCT03373422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study NCT03517150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular advancement device
Study NCT03517150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mandibular advancement device
Study NCT02319265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Oral liquid
Study NCT02319265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: Oral liquid
Study NCT04192292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Given at very low dose as a physiological stimulus on the beta cell not as medical treatment. 20mg gliclazide is being used in this study.
Study NCT04192292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP4 Inhibitor
Description: Given as a physiological stimulus to augment endogenous incretin hormone levels, not as a medical treatment. 100mg sitagliptin is being used in this study.
Study NCT00915421 — intervention group
Intervention type: PROCEDURE
Intervention: Induction of therapeutic mild hypothermia
Description: Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
Study NCT02090920 — intervention group
Intervention type: DRUG
Intervention: Nifedipine
Description: Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
Study NCT02056808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMT C1100
Description: Comparison of safety and pharmacokinetic of different dosages of drug
Study NCT03007472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI532
Description: Cochlear implant
Study NCT01406197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Vaginal progesterone
Description: Vaginal progesterone formulation (150 mg micronized progesterone daily)
Study NCT01406197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Topical progesterone
Description: Progesterone will be applied daily (150 mg micronized progesterone)by topical application
Study NCT01406197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Intramuscular progesterone
Description: Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
Study NCT03007472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 7
Description: Sound processor
Study NCT00269867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
Study NCT00269867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
Study NCT00269867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Description: Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
Study NCT02594150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
Study NCT00287261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg IV every 3 weeks for 36 weeks
Study NCT03922945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521 oral capsule
Description: Phentermine/Topiramate
Study NCT03922945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Inactive drug
Study NCT03922945 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle Modification
Description: The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
Study NCT03532464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
Study NCT03922945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: The lifestyle modification includes physical activity, behavior change, reduced calorie diet advice, and family support. This intervention is applied to all treatment groups.
Study NCT00714831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: 3-months physical activity intervention
Study NCT00714831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health educational program
Description: Health education sessions and stretching sessions
Study NCT03065010 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BCD-115
Description: Inhibitor of CDK8/19
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Oxygen]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.